| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8477737 | Molecular and Cellular Endocrinology | 2012 | 13 Pages |
Abstract
⺠Competitive AR antagonists with improved properties are being evaluated for treatment of prostate cancer. ⺠Novel compounds addressing alternative pockets, the N-terminal domain or the interaction with DNA have been identified. ⺠Steroidal SARMs are typically being used for treatment of hypogonadism. ⺠Non-steroidal SARMs are being tested clinically for the indications frailty syndrome and cachexia.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Bernard Haendler, Arwed Cleve,